Abstract:Abstract Although surgical debulking plus platinum-based chemotherapy induces clinical remission in 70+ % of patients with advanced ovarian carcinoma, most of these patients relapse and novel treatments are urgently needed. Although clinical trials of various immunotherapies have not yielded significant benefit for ovarian cancer, the failures can now be better understood as an outcome of the highly immunosuppressive tumor microenvironment so that one needs to both overcome this immunosuppression and concomitantly activate tumor-destructive immunological mechanisms. One way to achieve this is to use monoclonal antibodies (mAbs) to molecules which regulate the immune response. Antibodies blocking the co-inhibitory molecules CTLA-4 or PD-1 have already demonstrated encouraging clinical activity, particularly in melanoma, and the combination of the two mAbs has improved efficacy with long-lasting remission in some patients. We have evaluated the antitumor efficacy of mAbs against multiple co-signaling molecules, both individually and in combinations, in the ID8 syngeneic mouse model of ovarian cancer. In this model, small intraperitoneal tumor nests appear about 10 days after implantation and solid tumors as well as malignant ascites develop leading to death approximately 30 days after transplantation. Intraperitoneal injections of single mAb antagonists against co-inhibitory receptors (PD-1, CTLA-4, TIM-3, and LAG-3) or agonistic mAb targeting co-stimulatory molecules (CD137, OX40, GITR, and CD40) in mice that had been transplanted 10 days earlier with ID8 cells were ineffective. However, injection of a combination of anti-CD137 and anti-PD-1 mAbs significantly prolonged survival, and addition of a mAb to CTLA-4 further enhanced the antitumor efficacy with some mice surviving tumor-free >150 days. The mAb combination greatly increased the number of tumor-associated CD8+ effector T cells in the peritoneal cavity and decreased the number of immunosuppressive Treg and MDSC cells with a prominent increase in the T effector to T suppressive cell ratios, and it rescued the function of exhausted T cells with a PD-1+TIM3+ or PD-1+TIM3– phenotype. Importantly, pretreatment of the ID8-bearing mice with cisplatin, a drug routinely used to treat ovarian carcinoma, synergized with the anti-CD137/anti-CTLA4 mAb combination for a long-lasting and complete tumor regression in 80% of the mice. Our findings, as well as results from preclinical studies and clinical trials at many centers, strengthen the concept of targeting co-stimulatory and co-inhibitory molecules by immunomodulatory mAbs for cancer therapy. A variety of such receptors is known, and their significance as therapeutic targets, individually or in combinations, merits preclinical characterization and clinical testing of the best candidates. For example, we have recently shown that a combination of mAbs to CD137+PD1+CTLA4+CD19 is superior to the anti-CD137+PD1+CTLA4 combination when tested in mouse melanoma and lung carcinoma models and causes permanent regression of melanomas with a surface area of 80-100 mm2 at the onset of treatment, and we are now evaluating this and other combinations in the ID8 model. Although we have not observed significant toxicity, caution must be exercised since CD137 agonistic antibodies have been observed to cause liver toxicity in clinical trials. Restricting the biodistribution of mAbs for treating ovarian carcinoma to the peritoneal cavity and entrapping them in nanoparticles, may favor efficacy and minimize systemic toxicity. “Translation” of the preclinical findings to clinical trials in ovarian cancer patients should be seriously considered. Citation Format: Min Dai, Ingegerd Hellstrom, Yuen Yee Yip, Huafeng Wei, Karl Erik Hellstrom. Immunomodulatory antibodies for immunotherapy of ovarian cancer [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr AS24.

PD-1 Blockade and OX40 Triggering Synergistically Protects Against Tumor Growth in a Murine Model of Ovarian Cancer.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

Dual blockade of CXCL12‐CXCR4 and PD‐1–PD‐L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

OX40 Enhances T Cell Immune Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer

OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

Abstract AS24: Immunomodulatory Antibodies for Immunotherapy of Ovarian Cancer

Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model

OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment

OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.

Reprogramming Macrophage by Targeting VEGF and CD40 Potentiates OX40 Immunotherapy

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer

Abstract 3739: Different combination regimens for OX40 agonists and PD-1 inhibitors exert different antitumor effects in OX40 humanized mice

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer

Intratumoral injection of interferon gamma promotes the efficacy anti-PD1 treatment in colorectal cancer

Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer

IL-15 and anti-PD-1 augment the abscopal efficacy of agonistic intratumoral anti-CD40 in the TRAMP-C2 murine tumor model.

Expression of PD-L1 in Ovarian Cancer and Its Synergistic Antitumor Effect with PARP Inhibitor.

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma.